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Abstract
Background: The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) is a short assessment by which
neuropsychological symptoms can be detected and quantified in people with ALS. To avoid potential practice effects
with repeated administration, here we present alternative versions of the ECAS suitable for measuring change over time.
Objective: To develop two alternate versions of the ECAS: ECAS-B and ECAS-C. Method: One hundred and forty-nine
healthy adult participants were recruited. Thirty participants completed a pilot study in developing the alternate versions.
Two groups of 40 participants were administered the ECAS-B or ECAS-C and compared to published data of the original
ECAS (ECAS-A) to determine equivalence. An additional 39 participants were administered the ECAS consecutively,
either repeating the original version (ECAS-A-A-A) serially or the different versions (ECAS-A-B-C) to determine potential
practice effects. Recordings of assessments were scored by a second researcher to determine inter-rater reliability.
Results: No significant differences were found between versions (A, B, C) of the composite performance measures of ALS
Specific, ALS Non-Specific, and ECAS Total scores. Repeated serial administration of ECAS-A (A-A-A) produced some
practice effects for composite scores, whereas no such effects were found when alternate versions were administered serially
(A-B-C). Exceptionally high intra-class correlations were found for all three versions of the ECAS suggesting a high degree
of rater agreement. Conclusion: The newly developed alternate forms of the ECAS are both highly equitable to the original
ECAS-A and enable avoidance of practice effects, thus supporting their use in measuring cognition and behaviour
over time.
Keywords: Cognition, behaviour, screen, ECAS, alternate forms, reliability
Introduction
Up to 50% of patients with ALS will experience
changes in cognition and/or behaviour.
Considerable clinical (1,2), genetic (3), pathological
(4), and neuropsychological data (2–5) have demon-
strated that ALS and frontotemporal dementia
(FTD) significantly overlap. The observed cognitive
and behavioural changes in ALS parallel those
observed in frontotemporal dementia, namely, def-
icits in executive functions, language functions,
verbal fluency, and social cognition (6–9).
Similarly, behavioural features of ALS include
apathy, perseveration, and disinhibition (10–12).
Despite this overlap, cognitive and behavioural
symptoms in ALS do not always fall neatly into
the three recognized FTD subtypes: behavioural
variant FTD, non-fluent progressive aphasia and
semantic dementia, raising the question whether
ALS/FTD might be more than a simple juxtapos-
ition on ALS and FTD (13). This underlines the
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importance of an ALS-appropriate cognitive and
behavioural assessment.
However, the assessment of cognition in ALS
has been historically difficult due to the ubiquitous
requirement for intact motor functioning in neuro-
psychological assessment. The Edinburgh Cognitive
and Behavioural ALS Screen (ECAS) has been
recently developed to overcome this issue (14). The
ECAS has been designed to measure cognitive
functions, unrestricted by physical disability (15),
that are commonly affected in ALS (executive
functioning, language functioning, and verbal flu-
ency) in addition to functions less commonly
affected (memory and visuospatial functions).
Additionally, the ECAS includes a clinical caregiver
behaviour interview based on diagnostic criteria for
FTD (16). Although ECAS has been primarily
designed for use in ALS, it may be useful in all
patients in whom motor dysfunction might influence
their performance on cognitive tests, e.g.
Parkinsonism or paraplegia. The ECAS is a short
screening tool designed with high clinical utility and
is administrable by non-neuropsychological health
care professionals. It has been validated against a
comprehensive neuropsychological battery in
Scottish (17), German/Swiss-German (15,18),
Italian (19), Chinese (20), and Irish populations
(21).
Given the brevity of the ECAS and its accom-
modation for physical disability, it may be suitable
for measurement of changes in symptoms over the
course of the disease. Cognitive dysfunction may
have important implications for patient manage-
ment, treatment fidelity, power of attorney, and end-
of-life decision making (22–24). Behaviour change
has been linked to increased carer burden (25,26)
and shortened survival (27,28). As such, the accur-
ate assessment of cognition and behaviour over time
is of vital importance to meeting the needs of
patients and their families. However, it has been well
documented that the repeated administration of the
same neuropsychological test can result in an
improvement in performance (29). This improve-
ment, termed practice effects, may result from 1)
learning the content of test items, e.g., remembering
the content of a prose story to be remembered; and
2) development of test-taking strategies (30,31).
With regard to ALS, practice effects may mask
subtle deteriorations in cognition, or exaggerate
improvements due to intervention. Recently,
Burkhardt et al. (2016) demonstrated the presence
of practice effects with the ECAS whereby partici-
pants’ performance significantly improved over
serial assessments of six months (32).
A common method for overcoming practice
effects is the development of alternate versions of a
test in which elements of the test are changed while
retaining characteristic features and level of diffi-
culty (33). The aim of this study was to develop
alternate forms of the ECAS to permit repeated
assessment of cognitive functions in ALS over time,
and for the accurate monitoring of cognitive and
behavioural progression during the disease course.
Specifically, this study aimed to: (1) present two
alternate versions of the ECAS (ECAS-B and
ECAS-C); (2) investigate the equivalency of
the ECAS alternate forms to the original ECAS
(ECAS-A); (3) investigate whether alternate forms
of the ECAS reduce practice effects during serial
administration compared to repeated administration
of the original ECAS; and (4) investigate the inter-
rater reliability of all three versions of the ECAS.
Methodology
Participants
One hundred and forty-nine healthy adults were
recruited prospectively and matched by age, gender,
and education to that of the original publication of
the ECAS (14). Participants were representative of
the demographic profile of ALS patients.
Additionally, the previously published (retrospect-
ive) data on the ECAS (n¼ 40) were included in this
study (14), resulting in a total sample size of 189
participants. Participants were free of current or past
neurological or psychiatric conditions, reading/writ-
ing disabilities, and were not a blood relative of a
person with ALS. Participants were recruited from a
volunteer panel held by Edinburgh University, in
addition to local charitable organizations and com-
munity noticeboards.
Development of the ECAS-B and ECAS-C
The ECAS cognitive screen consists of 15 subtests
measuring five cognitive domains, namely:
Language, Verbal Fluency, Executive (ALS-
Specific) and Memory, Visuospatial (ALS Non-
Specific) functions. To develop alternate versions of
the ECAS cognitive screen, a pool of alternate
stimuli was generated for each subtest and piloted
on a sample of healthy adults. Stimuli selection and
development is described in supplementary mater-
ials. Arrays of stimuli were carefully selected and
formed into two alternate ECAS versions, the
ECAS-B and the ECAS-C. Selection of stimuli
was based on an item-by-item and group-level
exploration of response accuracy, in addition to
retaining semantic and linguistic characteristics
present in ECAS-A. The ECAS A, B, and C and
guidelines for usage are available on http://
ecas.psy.ed.ac.uk.
Procedure
Participants were recruited into six consecutive
groups across three study phases (Table 1). In
phase 1, a pool of alternate stimuli was generated to
produce two alternate forms of the ECAS (ECAS-B
and ECAS-C) and were administered to a sample of
2 C. J. Crockford et al.
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30 participants to broadly determine equivalence in
performance between corresponding sets of items in
these two versions. In phase 2, the ECAS-B and
ECAS-C were administered to two prospectively
recruited groups of 40 participants matched by age,
gender, and education to the data of 40 healthy
controls whose data were previously used to estab-
lish normative data for the ECAS-A (14).
In phase 3, an additional 39 participants were
randomly assigned to one of two conditions.
Participants were either administered the ECAS-A
three times consecutively (A-A-A), or administered
alternate forms of the ECAS (A-B-C). As practice
effects have shown susceptibility to short retest
intervals (e.g. see Calamia, Markon, & Tranel,
2012) and to maximize the possibility of detecting
such effects, participants were administered the
ECAS repeatedly during the same sitting. Phase 3
testing for each participant lasted approximately
50 min, limiting the possibility of fatigue. Between
each ECAS administration for both groups, partici-
pants completed a 5-min visual-search distractor
task or a 5-min rest to further reduce the possibility
of fatigue. Additionally, all prospective participants
were administered the Test of Premorbid
Functioning (TOPF) as an estimate of Full-Scale
IQ (FSIQ) (34).
The inter-rater reliability of all forms (A, B, and
C) of the ECAS was additionally explored. A subset
of participants consented to having their assessment
session audio-recorded (n¼ 94). These audio
recordings were then scored by a second rater,
trained to administer and score the ECAS by the
scale’s authors (14). Both raters (RR and CC) were
experienced in the administration and scoring of the
ECAS. When audio recordings were unclear or
given in written format, raw unscored paper forms
were provided.
All participants provided informed written con-
sent and this research was approved by the
Psychology Research Ethics Committee of the
University of Edinburgh.
Statistical analysis
Demographic data and estimated FSIQ were com-
pared across groups using a 2 test for categorical
data and one-way analysis of variance (ANOVA) for
continuous data. For all analyses, when distributions
or residuals violated statistical assumptions, power-
or log-transformations were applied. When trans-
formations failed to correct violations of test
assumptions, non-parametric alternatives were
used. Analyses were conducted using R 3.3.2. In
all cases, alpha was set to 0.05.
To explore the equivalence of the ECAS-A,
ECAS-B and ECAS-C forms, three analysis meth-
ods were employed on the scales’ targeted domains
(language, executive functioning, fluency, memory,
visuospatial), as well as ALS-Specific, ALS Non-
Specific, and ECAS Total scores. A one-way
ANOVA or Kruskal-Wallis test was used to com-
pare the alternate forms’ means or medians (as
appropriate). Kolmogorov-Smirnov tests were
employed to compare the shape and spread of the
distribution for ECAS-B and ECAS-C compared
to ECAS-A. Standard null hypothesis significance
testing does not directly assess the equivalence of
data, but rather tests the evidence against the null.
As such, the one-way ANOVA and Kolmogorov-
Smirnov tests were employed to assess whether
means and distribution of scores on the ECAS
alternate forms significantly differ. Consequently, a
Bayesian ANOVA was employed to directly test the
null hypothesis and examine the probability that
the ECAS alternate forms are the same. Bayes
factors for the null hypothesis were calculated using
medium prior of 0.7. Due to significant rates of
ceiling effects in the Language and Visuospatial
domains of the ECAS, Fisher’s exact test for count
data was used.
Possible practice effects of using ECAS A-A-A
versus ECAS A-B-C were explored using a mixed
effects model with Time and Group (A-A-A versus
A-B-C) and a random intercept and slope fitted for
each participant. To explore the differential impact
of Group the interaction term (Time*Group) was
added to the model. p values were obtained for the
mixed effect model by likelihood ratio tests of the
full model (Time*Group) against a reduced model
without the interaction term.
Finally, inter-rater reliability of all three forms of
the ECAS was explored using intra-class correlation
(ICC) to determine the degree of agreement
between two independent raters. ICCs and their
95% confidence intervals were calculated based on
Table 1. Description and function of participant groups.
Phase Function Procedure n
Phase 1: Pilot study ECAS-B and ECAS-C formation Administered array of possible stimuli 30
Phase 2: Establishing normative data Establish normative data and
equivalence of alternate forms
Administered ECAS-A 40
Administered ECAS-B 40
Administered ECAS-C 40
Phase 3: Exploring practice effects Measure relative practice effects of
administering same versus dif-
ferent ECAS forms
Administered ECAS-A serially 20
Administered ECAS-A, ECAS-B, and
ECAS-C sequentially
19
Alternate forms of ECAS 3
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mean-rating, absolute-agreement, two-way random-
effects models (35).
Results
ECAS B and ECAS C: Normative data and
equivalency
Prospectively recruited participants (n¼ 80) were
randomly assigned to one of two groups and
matched by age, gender, and education to a third
retrospectively collected group (n¼ 40). No signifi-
cant differences were observed for background
demographic data, nor for estimated FSIQ between
the two prospectively recruited groups (Table 2).
Mean performance for each ECAS cognitive
domain across alternate forms was similar (Table 3).
Results of one-way ANOVAs, Kruskal-Wallis, and
Kolmogorov Smirnov tests demonstrated no signifi-
cant differences between forms in the domains of
Fluency, Executive Functions, and Memory.
Additionally, no significant differences were
observed for the ALS Non-Specific, ALS Specific,
and ECAS Total composite scores. Fisher’s exact
test for Language revealed no significant difference
in the frequency of scores obtained (p¼ 0.147).
Conversely, the Visuospatial domain was signifi-
cantly different across ECAS versions (p¼ 0.013).
This difference was, however, entirely driven by a
larger proportion of participants for ECAS-B and
ECAS-C making a single error (i.e. scoring 11 out
of 12).
Thresholds for impairment for the alternate
versions (ECAS-B and ECAS-C) demonstrate
parity across all versions using both 2 standard
deviations and the 95th percentile. Cut-offs for
impairment are retained from ECAS-A for the
ECAS-B and ECAS-C (Supplementary Table 2).
Practice effects
Participants were randomly assigned to one of two
conditions; the ‘same’ group received ECAS-A three
times serially (A-A-A), while the ‘different’ group
was administered ECAS-A followed by ECAS-B
and ECAS-C (A-B-C). No significant differences
were observed between groups in age, gender, and
education (Table 4). One-way repeated analysis of
variance for the ECAS A-A-A group demonstrated a
significant improvement over time for ALS Specific
(F(2,38)¼ 5.68, p¼ 0.007), ALS Non-Specific
(F(2,38)¼ 100.42, p50.001), and ECAS Total
Scores (F(2,38)¼ 25.88, p50.001) as displayed in
Figure 1. Additionally, the executive and memory
subdomains and the majority of their subtests
demonstrated a significant improvement over time
(See Supplementary Table 3). No significant differ-
ences were observed in ALS Specific, ALS Non-
Specific, or ECAS Total Scores for participant in the
ECAS A-B-C group, nor any cognitive subdomains
or subtests.
A significant group difference was observed in
baseline ECAS-A Total score (t(36.72)¼ 3.03,
p¼ 0.005) with those in the ECAS A-B-C group
performing better than the ECAS A-A-A. However,
a six-point difference was observed between groups
for estimated FSIQ. While this did not reach
statistical significance, a linear regression model
demonstrated a significant positive effect of IQ on
ECAS Total Score (F(1,34)¼ 13.67, p50.001,
¼ 0.449) explaining 28.67% of the variance.
Table 3. Comparison of performance across independent groups for the ECAS A, B, and C.
Domain ECAS-A ECAS-B ECAS-C ANOVA KS A-B KS A-C Bayes BF01
Language 27.620.70 27.181.15 27.12 0.99 – – – –
Fluency 19.852.50 19.702.99 20.45 3.09 0.190* 0.999 0.914 6.72
Executive Functions 40.483.54 40.234.05 39.77 3.70 0.703 0.999 0.759 9.43
Memory 18.682.73 18.622.17 18.30 3.21 0.906 0.573 0.914 10.52
Visuospatial 11.850.48 11.450.81 11.43 0.90 – – – –
ALS-Specific 87.954.98 87.105.77 87.35 5.34 0.775 0.914 0.914 10.14
ALS Non-Specific 30.522.96 30.072.39 29.73 3.62 0.519 0.164 0.759 7.09
ECAS Total 118.476.64 117.177.15 117.08 7.12 0.610 0.164 0.573 8.34
*Kruskalskal-Wallis test. KS¼Kolmogorov-Smirnov test. BF01¼Bayes factor for the null hypothesis. Due to ceiling effects, statistical
analysis here was not appropriate for language and visuospatial functions.
Table 2. Demographic characteristics of independent ECAS A,
B, and C groups.
ECAS-A
(n¼40)
ECAS-B
(n¼40)
ECAS-C
(n¼ 40) p
Age 59.2012.58 60.20 15.32 58.52 14.28 0.856
Gender
(Male)
45% 45% 43% 0.967
Education
(Years)
12.282.52 13.843.25 13.38 3.25 0.086
TOPF* – 106.5111.90 105.469.81 0.670
*TOPF (Test of Premorbid Function) unavailable for retrospect-
ive data. Welch t-test applied.
Table 4. Demographic characteristics of ECAS A-B-C (different)
and ECAS A-A-A (same) groups.
Different (n¼ 19) Same (n¼20) p
Age 55.0010.32 57.25 12.67 0.546
Gender (Male) 57.89% 50% 0.863
Education (Years) 16.21 2.52 15.532.54 0.401
TOPF 113.19 10.20 107.3010.63 0.099
TOPF¼Test of Premorbid Functioning.
4 C. J. Crockford et al.
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Due to this small but significant difference in
baseline performance between groups, a linear
mixed effect model was fit. The addition of an
interaction term (Group*Time; b¼ 3.44,
SE¼ 0.859) significantly contributed to the fit of
the ECAS Total model (2(1)¼ 13.43, p50.001). A
similar significant Time*Group interaction was
observed for ALS Non-Specific functions
(b¼ 2.25, SE¼ 0.341, p50.001), but not for ALS
Specific functions (b¼ 1.20, SE¼ 0.77, p¼ 0.127).
The effect of Time*Group was significant for
ECAS Total and ALS Non-Specific functions, even
accounting for a random intercept and slope for
each participant (i.e. individual variation in baseline
performance and rate of change), suggesting that the
rate of improvement of using the ECAS-A serially is
significantly greater than using the ECAS alternate
forms.
Inter-rater reliability
Mean-rating, absolute-agreement, two-way random
effects ICC models were generated for each cogni-
tive domain and version of the ECAS. Across all
versions of the ECAS and for all cognitive domains,
inter-rater reliability was excellent ranging from
0.930 to 0.998. Supplementary Table 1 displays
the respective ICC, 95% confidence intervals, and
model statistics for each comparison; in all cases
p50.001 indicated significant agreement between
independent raters.
Discussion
The ECAS was developed to accurately assess
cognitive functions in patients with ALS while
controlling for motor disability. Not only has the
ECAS shown high sensitivity and specificity to
cognitive impairment against a full neuropsycho-
logical battery (17–21), it has high clinical utility in
describing the nature of these impairments.
Monitoring progression of cognitive and behavioural
symptoms may have important implications for
patient management, treatment, prognosis, end-of-
life decision making, and caregiver burden (22–28).
The purpose of this study was to develop alternate
forms of the ECAS to facilitate repeated assessment
and longitudinal monitoring of cognition and behav-
iour in patients with ALS. Particularly, the aims
were to present and determine equivalency of two
alternate forms of the ECAS (ECAS-B and ECAS-
C) to the original ECAS-A, to investigate whether
alternate forms of the ECAS reduce practice effects
relative to the ECAS-A, and to investigate the inter-
rater reliability of all three forms of the ECAS.
The findings in this study provide strong evi-
dence that the newly developed ECAS-B and
ECAS-C are equivalent to that of the original
ECAS-A. Results of independent group analysis
suggest that (1) performance on the alternate forms
does not significantly differ from the original ECAS;
and (2) there is strong evidence that the alternate
forms come from the same distribution of scores.
While a single significant difference was observed for
the visuospatial domains of the ECAS, examination
Figure 1. Comparison of practice effects using the same (A-A-A) versus different (A-B-C) versions of the ECAS.
Alternate forms of ECAS 5
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of the score distribution revealed that this is due to
ceiling effects and driven by a one- point difference
in the alternate versions, therefore not affecting the
equivalence of the alternate forms.
To establish the utility of the alternate forms in
reducing practice effects, the ECAS-A was admin-
istered serially to a group of participants and
compared to a separate group who were adminis-
tered the alternate versions of the ECAS. Results of
this study suggest significant practice effects exist for
the ECAS-A when administered serially. This
finding is in agreement with recent research
demonstrating that the ECAS-A is susceptible to
practice effects with repeated administration (32).
The present study was designed to maximize the
possible detection of practice effects as short inter-
vals have been shown to exacerbate such an effect
(29). However, no significant change in perform-
ance was detected over time when alternate versions
of the ECAS were administered. Additionally, a
significant Time by Group (i.e. time representing
repeated assessment and group representing partici-
pants who received the same or different versions of
the ECAS) interaction was observed when the
ECAS A-A-A group was compared to the ECAS
A-B-C group. The mixed effects model used in the
analyses considered individual variability over time
and baseline performance for each participant,
suggesting that differences in practice effects were
not due to individual variation. Rather, evidence
herein suggests that the use of alternate versions
of the ECAS is successful in reducing practice
effects present in the repeated administration of the
ECAS-A.
Cut-off scores, based on 2 standard deviations
(SD) below the mean, for abnormality have previ-
ously been reported for the ECAS-A (14) and
validated against a full neuropsychological battery
(17). The present study demonstrated that the
newly presented alternate versions are highly equiva-
lent to the original ECAS. Examination of the cut-
off scores for the alternate versions (ECAS-B and
ECAS-C) demonstrate equality across all versions
using two common methods (i.e. 2 standard devi-
ations below the mean and the 95th percentile). For
example, using a threshold of 2 SDs, the cut-offs for
ALS-Specific functions is 77, 75, and 76 for versions
A, B, and C, respectively. Similarly, cut-offs using
the 95th percentile for ECAS Total scores are 105
for both ECAS-B and ECAS-C, where the pub-
lished cut-off for ECAS-A is also 105. Given the
lack of clinically meaningful differences between
versions, the lack of observable practice effects, and
similar cut-offs using two different methods, the cut-
offs for the ECAS-A have been retained for the
alternate versions and are displayed in
Supplementary Table 2.
An additional goal of this study was to explore
the inter-rater reliability of the ECAS and its
alternate form. The administrations of the ECAS
in this study were audio-recorded and scored by a
second independent rater. Agreement for all cogni-
tive domains and versions of the ECAS ranged
between 0.930 and 0.998, providing evidence of
exceptionally high agreement. While these findings
are promising, one caveat here is that both raters
had a background in psychology and were trained in
the use of the ECAS by the scale’s authors. Care
should be taken in inferring generalisability in rater
agreement between health care professionals with
different professional backgrounds (e.g. nurses,
neurologists). However, the two raters in this study
(CC and RR) were highly experienced in adminis-
tering the ECAS resulting in an excellent level of
agreement. This highlights the benefit of appropri-
ate training in the standardization of assessment
and, as such, training is recommended for all health
professionals using the ECAS.
The findings of this study provide strong evi-
dence that the alternate versions of the ECAS are
equitable to the original ECAS and allow for the
longitudinal monitoring of cognitive function in
individuals with ALS. However, some further
research is required to explore how the alternate
versions function over time. In this study, the
alternate forms were presented in a fixed order (A-
B-C) and for practical purposes this order is
therefore recommended. While no evidence of
order effects was found herein, future research
may explore order effects using randomized presen-
tation. Furthermore, reliable measures of change are
needed to determine what change in performance is
over and above normal variation and constitutes a
significant improvement or decline in function.
Methods such as the Reliable Change Index or
regression based methods will in the future allow for
this.
Ceiling effects were observed in all three versions
of the ECAS for the language and visuospatial
domains. While ceiling effects are common in
neuropsychological tests, they limit the certainty
with which equivalency can be assumed. It would be
beneficial to explore the relative practice effects of
using the same versus different ECAS versions in an
ALS sample whom are less likely to approach
ceiling.
Finally, future research may explore the effect of
different testing intervals on repeated assessment.
Testing intervals of 4, 6, and 12 months may be
common within research and clinical practice and
the effect of interval length should be explored in
relation to reliability statistics of the ECAS alternate
versions.
In conclusion, our findings suggest that the
ECAS-B and ECAS-C are demonstrably equivalent
to the original ECAS and provide the opportunity to
monitor the longitudinal cognitive and behavioural
profile of people with ALS longitudinally while
controlling for practice effects both clinically and in
research settings. Therefore, the neuropsychological
6 C. J. Crockford et al.
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profile may be monitored over the course of the
disease allowing clinicians to provide time-appro-
priate, accurate, and person-centred care services.
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